Most existing KRAS G12C inhibitors such as Sotorasib or MRTX849 have shown remarkable efficacy in KRAS G12C driven cancers such as non-small cell lung cancer [21,22,23,24] but limited effect on PDAC due to the rare occurrence of G12C mutation cases. Here, KRAS is linked to cancer.